CNSX:EHC

Stock Analysis Report

Executive Summary

Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Eviana Health's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.8%

EHC

4.2%

CA Chemicals

-0.1%

CA Market


1 Year Return

-85.8%

EHC

-13.8%

CA Chemicals

0.9%

CA Market

Return vs Industry: EHC underperformed the Canadian Chemicals industry which returned -13.8% over the past year.

Return vs Market: EHC underperformed the Canadian Market which returned 0.9% over the past year.


Shareholder returns

EHCIndustryMarket
7 Day-10.8%4.2%-0.1%
30 Day-23.3%-2.1%-2.1%
90 Day-50.0%-1.0%-1.6%
1 Year-85.8%-85.8%-10.9%-13.8%4.4%0.9%
3 Yearn/a-5.0%-10.5%15.5%5.2%
5 Yearn/a-23.5%-31.1%25.7%7.5%

Price Volatility Vs. Market

How volatile is Eviana Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eviana Health undervalued compared to its fair value and its price relative to the market?

0.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate EHC's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate EHC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EHC is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: EHC is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate EHC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EHC is good value based on its PB Ratio (0.8x) compared to the CA Chemicals industry average (1.2x).


Next Steps

Future Growth

How is Eviana Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eviana Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Eviana Health performed over the past 5 years?

-47.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: EHC is unprofitable, and losses have increased over the past 5 years at a rate of -47.1% per year.

Accelerating Growth: Unable to compare EHC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EHC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-25.7%).


Return on Equity

High ROE: EHC has a negative Return on Equity (-87.79%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: EHC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: EHC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Eviana Health's financial position?


Financial Position Analysis

Short Term Liabilities: EHC's short term assets (CA$11.1M) exceeds its short term liabilities (CA$2.3M)

Long Term Liabilities: EHC's short term assets (11.1M) exceeds its long term liabilities (8.0M)


Debt to Equity History and Analysis

Debt Level: EHC's debt to equity ratio (170%) is considered high

Reducing Debt: Insufficient data to determine if EHC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: EHC has a high level of physical assets or inventory.

Debt Coverage by Assets: EHC's debt is covered by short term assets (assets are 1.387650x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EHC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EHC has sufficient cash runway for 1.493625 years if free cash flow continues to reduce at historical rates of -85.4% each year.


Next Steps

Dividend

What is Eviana Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate EHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EHC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if EHC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EHC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EHC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Eviana Health's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average board tenure


CEO

Avram Adizes 0

2.2yrs

Tenure

CA$120,000

Compensation

Dr. Avram Adizes, Ph.D., P.E., serves as the Chief Technology Officer of Phoenix Capital Partners Inc. Dr. Adizes is responsible for Technology assessment and evaluation. Dr. Adizes serves as Chairman and  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Avram's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Insufficient data to compare Avram's compensation with company performance.


Board Age and Tenure

2.2yrs

Average Tenure

Experienced Board: EHC's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellCA$7,50028 Jan 19
Olivier Robert Benloulou
EntityIndividual
Shares10,000
Max PriceCA$0.75
SellCA$55,93031 Oct 18
Olivier Robert Benloulou
EntityIndividual
Shares65,800
Max PriceCA$0.85

Ownership Breakdown


Management Team

  • Sydney, Syd Au

    CFO & Director

    • Tenure: 6.3yrs
    • Compensation: CA$60.00k
  • Avram Adizes

    Chairman of the Board & CEO

    • Tenure: 2.2yrs
    • Compensation: CA$120.00k
  • Patrick Brown

    Vice-President of Business Development & Corporate Communications

    • Tenure: 1.4yrs

Board Members

  • Paolo De Luca (46yo)

    Director

    • Tenure: 1yrs
  • Sydney, Syd Au

    CFO & Director

    • Tenure: 6.3yrs
    • Compensation: CA$60.00k
  • Avram Adizes

    Chairman of the Board & CEO

    • Tenure: 2.2yrs
    • Compensation: CA$120.00k
  • Joel Sherlock

    Member of Advisory Board

    • Tenure: 1.3yrs
  • Ljiljana Vujotic

    Director

    • Tenure: 2.2yrs
    • Compensation: CA$100.00k

Company Information

Eviana Health Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eviana Health Corporation
  • Ticker: EHC
  • Exchange: CNSX
  • Founded: 2011
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: CA$4.421m
  • Shares outstanding: 23.90m
  • Website: https://eviana.ca

Location

  • Eviana Health Corporation
  • 5728 East Boulevard
  • Vancouver
  • British Columbia
  • V6M 4M4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EHCCNSX (Canadian National Stock Exchange)YesCommon SharesCACADSep 2017
EVNN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2017
1CPDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2017

Biography

Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pe ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:38
End of Day Share Price2019/10/11 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.